AIKENING Gx390 Recoil Starter Pull Start Assembly with Recoil Starter Rope Pull for Honda Recoil Starter(Pack of 2) Recoil Starter Rope X3 Bolts X9

Product Information

Hansen, E.; Zadura, L.; Frankowski, S.; Wachowicz, M. Upgrading of an activated sludge plant with floating biofilm carriers at Frantschach Swiecie S.A. to meet the new demands of year 2000. Water Sci. Technol. 1999, 40, 207–214. [ Google Scholar] [ CrossRef] Frontier Biotechnologies Inc. A multicenter, two-arm, 24-week study of albuvirtide in combination with 3BNC117 in patients with multi-drug resistant (MDR) HIV-1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on September 17, 2020. NLM Identifier: NCT04560569. Accessed April 5, 2023

National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development. Accessed April 5, 2023 Dr Dong Xie, Chief Scientific Officer, Chairman, Frontier Biotechnologiessaid, "IAS is the world's most influential meeting on HIV science. It leads the collective response on every front of the global HIV community. Frontier Biotechnologiesis delighted to break the TALENT study results, through the investigators, at this prestigious meeting. ABT+LPV/r (Albuvirtide plus boosted Lopinavir combination) is a preferred two-drug regimen as ABT is active against most HIV strains, including resistant strains, and has a high resistance barrier, while LPV/r is widely available in China. This is a robust example of a combination of two classes of drugs with different mechanisms of action providing a combination of complementary efficacies. Two NRTIs were replaced with Aikening® as the core, and rapid and persistent viral suppression was achieved in patients who failed initial treatment." In vitroantiretroviral activity Albuvirtide-albumin conjugates against various HIV-1 strains showed the IC50of Albuvirtideagainst 8 HIV-1 subtypes (A, B, C, G and EA recombinants) was 0.5~4.8 nM in human peripheral blood mononuclear cells (PBMCs). The meanIC50 of Albuvirtide against 28 prevalent strains of CRF07-BC, CRF01-AE, and B' subtypes from China were 5.2 nM, 6.9 nM and 9.5 nM, respectively. Study Purpose: The purpose of this open-label trial was to evaluate 1) the drug-drug interaction between albuvirtide and lopinavir/ritonavir and 2) the short-term safety and efficacy of albuvirtide plus lopinavir/ritonavir.Nie J, Sun F, He X, et al. Tolerability and adherence of antiretroviral regimens containing long-acting fusion inhibitor albuvirtide for HIV post-exposure prophylaxis: a cohort study in China. Infect Dis Ther. 2021;10(4):2611-2623. doi:10.1007/s40121-021-00540-5. Accessed April 5, 2023 Have all the materials ready before starting the dose preparation to minimize the overall preparation time. Use aseptic technique when preparing and administering the dose. Participants have HIV RNA <50 copies/mL at screening and have had HIV RNA <50 copies/mL in the past 24 weeks prior to screening. Jin, X.Y.; Chen, J.L.; Li, A.M. Study on the catalytic oxidation of wastewater containing phenol with chlorine dioxide as oxidant. Ion Exch. Adsorpt. 2003, 19, 61–66. [ Google Scholar]

Acetyl-Trp-Glu-Glu-Trp-Asp-Arg-Glu-Ile-Asn-Asn-Tyr-Thr-(N-{2-[2-(N-(3-maleimidepropionyl)amino)ethoxy]ethoxy}acetyl)Lys-Leu-Ile-His-Glu-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leucinamide In the embryo-fetal development toxicity study in Wistar rats, the pregnantrats were givenAlbuvirtideby intravenous injection at dose level of30, 60and120 mg/kg once every 2 days from the 6thto 16thday of pregnancy.No significant changes were observed in pregnant rats, embryo and fetal appearance, skeleton and internal organs. The NOAEL of Albuvirtideforthe parental pregnant rats,and embryos-fetusdevelopment were both 120 mg/kg, i.e. 4 foldsofhuman equivalent dosecalculatedin terms of body surface area. Toxicokinetic study revealedno significant accumulation of Albuvirtidein pregnant rats. The efficacy of AIKENING TM is mainly based on analyses of data from a dose exploration studyand an on-going pivotal study (TALENT study). Primary endpoint: Proportion of patients with with plasma viral load (HIV-RNA) level<50 copies/mL at Week 48 by FDA snapshot algorithm VIENNA, Austria, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying Specific Active Immunotherapies (SAITs), today announced an exclusive collaboration and license agreement with Frontier Biotechnologies Inc. (688221.SH), a commercial-stage biopharmaceutical company, for the development and commercialization of AFFITOPE ® AT04 for the treatment of patients with hypercholesterolemia in the Greater China region, including mainland China, Hong Kong, Macau and Taiwan. AFFITOPE ® AT04 is a potential first-in-class investigational active immunotherapy targeting PCSK9, with results of a large phase 1 clinical study having recently been published. Shanghai-based Lynx Financial served as the sole financial advisor in this transaction.In the reproductive toxicity studies in rat and rabbit, the No Observed Adverse Effect Level(NOAEL) of Albuvirtideintravenously injected were 4 folds and 2 folds of humanequivalent dose, respectively, and no toxicity to parental fertility and embryonic development was observed. Since no clinical data are availablein pregnant women, it is not recommended that this product be used for pregnant women. Thein vivoantiviral activity of subcutaneous injection of Albuvirtidewas evaluatedin SCID-hu Thy/Liv mice model that was constructed by transplantation of human fetal thymus and liver into immunodeficient CB-17-SCID mice and inoculation with HIV-1. Albuvirtideshowed strong antiviral activity in mice at a dose of 10 mg/kg whether Albuvirtide was administered by subcutaneous injectiononce a day or every other day (equalto around 2 and 4 half-lifeintervals of mouse albumin, respectively).

The prepared dose should be administered as soon as possible (or within 30 minutes after end of reconstitution). Discard the dose if the infusion is not started within 30 min after the end of dose preparation and re-prepare the dose with a fresh vial. Uğurlu, M.; Karaoğlu, M.H. Removal of AOX, total nitrogen and chlorinated lignin from bleached Kraft mill effluents by UV oxidation in the presence of hydrogen peroxide utilizing TiO 2 as photocatalyst. Environ. Sci. Pollut. Res. 2009, 16, 265–273. [ Google Scholar] [ CrossRef] [ PubMed]Junna, J.; Ruonala, S. Trends in water pollution control in the finnish pulp and paper industry. Water Sci. Technol. 1991, 24, 1–10. [ Google Scholar] [ CrossRef] Participants are adults with HIV who have received ART for at least 6 months. Participants have been on a failing ART regimen for at least 8 weeks prior to screening or had treatment failure within the past 8 weeks of screening and are off therapy. Selected Study Results: Results published in AIDS Research and Therapy (2016) showed that there was little to no drug-drug interaction between albuvirtide and lopinavir/ritonavir. Additionally, albuvirtide combined with lopinavir/ritonavir was safe and effective in reducing viral load levels, with the higher albuvirtide dose tested having greater anti-HIV activity than the lower albuvirtide dose tested. 5 TALENT was a multicenter, open, randomized, non-inferiority clinical phase III study. The objective was to evaluate the safety and efficacy of AIKENING TM combined withLPV/rfortreatment ofHIV-1 infected patients who failed standard first-line ART. The studywas designed to enroll 420 subjects for 48-week treatment with 7 visits. All subjects were randomized at 1:1 ratio to the treatmentand control group. Subjects in the treatment group received AIKENING TM 320mg once a day on day 1, 2, 3 and 8, and then once a week, combined with LPV/r for 48 weeks. Subjects in the control group receiveda 3-drugcombinationof LPV/r + Tenofovir (TDF) or Zidovudine (AZT) + Lamivudine (3TC) for 48 weeks. The primary efficacy endpoint was the proportion of patients with the HIVRNA < 50 copies/ml at 48 week(by FDA Snapshot Algorithm).The second efficacy endpoints included the mean change of HIV RNA from baseline, the proportion of patients with the HIVRNA< 400 copies/ml (by FDA Snapshot Algorithm), and the mean changeof CD4cell countfrom baseline after treatment.